Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bicycle Therapeutics plc - American Depositary Shares
(NQ:
BCYC
)
14.68
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bicycle Therapeutics plc - American Depositary Shares
< Previous
1
2
3
4
5
6
7
Next >
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday
December 18, 2024
Via
Benzinga
Breaking Down Bicycle Therapeutics: 8 Analysts Share Their Views
December 16, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 13, 2024
Via
Benzinga
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
December 13, 2024
Via
Benzinga
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
December 13, 2024
Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 gene amplification.
Via
Benzinga
Navigating 11 Analyst Ratings For Bicycle Therapeutics
October 24, 2024
Via
Benzinga
In-Depth Examination Of 5 Analyst Recommendations For Bicycle Therapeutics
September 06, 2024
Via
Benzinga
The Latest Analyst Ratings For Bicycle Therapeutics
August 07, 2024
Via
Benzinga
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification
December 12, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts
December 10, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update
November 25, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
November 12, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
October 31, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals
October 23, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress
October 16, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
BCYC: A Promising Play In The Biotech Sector
October 01, 2024
The long-awaited and overdue half-point cut in the federal funds rate was the impetus for the SPDR Biotech ETF to finally break above the 102-103 level. Meanwhile, Bicycle Therapeutics Plc. had a...
Via
Talk Markets
Topics
ETFs
Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024
September 14, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
September 06, 2024
RBC Capital initiates coverage on Bicycle Therapeutics, highlighting Zelenectide's potential in oncology with improved safety over competitors. The analyst projects ~$2 billion in peak sales by 2033...
Via
Benzinga
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
August 21, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
BCYC stock results show that Bicycle Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
August 06, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024
July 22, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
June 03, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting
May 23, 2024
From
Bicycle Therapeutics plc
Via
Business Wire
Dow Dips Over 550 Points; BJ's Wholesale Club Earnings Beat Views
May 23, 2024
Via
Benzinga
Topics
Earnings
Stocks
Exposures
Financial
US Equities
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.